ARV-806 / Arvinas - LARVOL DELTA

ARV-806: Novel PROTAC KRAS G12D degrader (Arvinas Press Release) - "Continue enrollment in the Phase 1 trial of ARV-806 in patients with solid tumors harboring KRAS G12D mutations (ClinicalTrials.gov Identifier: NCT07023731); Share initial clinical data in patients with solid tumors harboring KRAS G12D mutations (2026)."

P1 data • Solid Tumor

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) - "In vitro, ARV-806 degraded KRAS G12D with picomolar potency across pancreatic, colorectal, and lung cancer cell lines but did not induce degradation of wild-type and other mutant RAS isoforms....ARV-806 demonstrated robust efficacy responses at low doses in tumor models including: ≥30% tumor volume reductions in pancreatic and colorectal cell line-derived xenograft (CDX) models and a patient-derived xenograft (PDX) model of lung cancer."

Preclinical • Colorectal Cancer • Non Small Cell Lung Cancer • Pancreatic Cancer

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)

Preclinical • Solid Tumor

Preclinical activity of ARV-806, a PROTAC KRAS G12D degrader (AACR-NCI-EORTC 2025) - P1/2 | "Additionally, in the mutant KRAS CT26 syngeneic in vivo model, robust single-agent activity was observed as well as strong synergy with immune checkpoint blockade, all resulting in antitumor immunological memory. These combined observations suggest that PROTAC KRAS degraders may be particularly adept at attacking tumors by both eliminating the key oncogenic driver protein and by activating an antitumor immune response."

IO biomarker • Preclinical • Colorectal Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • BCL2L11 • KRAS • MYC

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) - "Added a combination cohort of vepdegestrant plus Pfizer’s KAT6 inhibitor (PF-07248144) to Pfizer’s ongoing Phase 1 clinical trial (ClinicalTrials.gov Identifier: NCT04606446)....ARV-393: Oral PROTAC BCL6 degrader: Continued recruiting patients in the first-in-human Phase 1 clinical trial in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) (ClinicalTrials.gov Identifier: NCT06393738)....ARV-806: Novel PROTAC KRAS G12D degrader: Initiated enrollment in the Phase 1 clinical trial evaluating ARV-806 in patients with solid tumors harboring KRAS G12D mutations (ClinicalTrials.gov Identifier: NCT07023731)."

Trial status • Castration-Resistant Prostate Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Negative Breast Cancer • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Solid Tumor

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) - "ARV-393: Oral PROTAC BCL6 degrader - Share preclinical data in combination with glofitamab in models of aggressive high grade DLBCL (2H 2025). Share preliminary clinical data from the ongoing Phase 1 clinical trial in patients with NHL (ClinicalTrials.gov Identifier: NCT06393738) (2H 2025). ARV-806: Novel PROTAC KRAS G12D degrader - Share preclinical data from the clinical stage ARV-806 program (2H 2025)."

P1 data • Preclinical • Diffuse Large B Cell Lymphoma • Non-Hodgkin’s Lymphoma

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation (clinicaltrials.gov) - P1/2 | N=159 | Recruiting | Sponsor: Arvinas Inc.

New P1/2 trial • Oncology • Solid Tumor • KRAS

Anticipated Upcoming Milestones and Expectations (GlobeNewswire) - "Share data with global regulatory authorities to potentially support regulatory filings (2Q 2025) and submit new drug application to the U.S. Food and Drug Administration for potential approval (2H 2025); Add a combination cohort of vepdegestrant plus Pfizer’s KAT6 inhibitor (PF-07248144) to Pfizer’s ongoing Phase 1 trial (NCT04606446)....ARV-806: Novel PROTAC KRAS G12D degrader: Initiate a first-in-human Phase 1 trial in patients with solid tumors harboring KRAS G12D mutations (2H 2025)."

FDA filing • Filing • New P1 trial • Trial status • Solid Tumor

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) - "ARV-393: Oral PROTAC BCL6 degrader: Present preclinical data of ARV-393 in combination with standard of care biologic agents and small molecule inhibitors in high grade and aggressive diffuse large B-cell lymphoma in vivo models at the American Association for Cancer Research Annual Meeting (April 25-30, 2025). Disclose preliminary data from the ongoing Phase 1 clinical trial in patients with NHL (ClinicalTrials.gov Identifier: NCT06393738) in 2025....Novel PROTAC KRAS G12D degrader: File an Investigational New Drug (IND) application in 2025."

IND • P1 data • Preclinical • Diffuse Large B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Solid Tumor

Arvinas…Highlights Upcoming Milestones, and Provides Corporate Update (GlobeNewswire) - "ARV-393: Oral PROTAC BCL6 degrader - Present initial data from the ongoing Phase 1 clinical trial in patients with B-cell lymphomas (NCT06393738). Novel PROTAC KRAS G12D degrader: File an Investigational New Drug (IND) application."

IND • P1 data • Non-Hodgkin’s Lymphoma • Oncology

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) - "ARV-393: Oral PROTAC BCL6 degrader - Continue recruiting patients in the first-in-human Phase 1 clinical trial evaluating ARV-393 in patients with B-cell lymphomas. Novel PROTAC KRAS G12D degrader: File an Investigational New Drug (IND) application in 2025."

IND • Trial status • Non-Hodgkin’s Lymphoma